NCT01607125View on ClinicalTrials.gov

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2013

Conditions

Depression

Interventions

DRUG

Vortioxetine (Lu AA21004)

encapsulated 20 mg tablets, orally, once daily for 13 to 14 days

DRUG

Placebo

capsules, orally, once daily for 13 to 14 days

Trial Locations (1)

OX3 7JX

GB001, Headington

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY

NCT01607125 - Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls | Biotech Hunter | Biotech Hunter